QIAGEN Clinical Insight bioinformatics platform expanded

The QIAGEN Clinical Insight (QCI) clinical decision support solution streamlines the annotation, interpretation and reporting of next-generation sequencing results (NGS) for clinical laboratories. The bioinformatics platform has been expanded from interpreting NGS data on somatic mutations in solid tumour cancers to add leukaemia and lymphoma testing, as well as testing for hereditary cancer indications.

The product enables labs to efficiently provide the valuable molecular insights made possible by next-generation sequencing. For somatic cancer indications, the enhancements include insights for diagnostic testing as well as monitoring and progression, support for copy number variations (CNVs) and fusion genes, and additional prognostics data from the literature.

The unit now provides comprehensive cover of FDA- and EMA-approved drug labels, NCCN, ASCO and ESMO professional guidelines, and active genotype-related clinical trials to complement comprehensive coverage of literature references and a wide range of reported case databases. The enhancements also add 32 hereditary cancer genes to QCI's coverage, providing a more complete solution for laboratories to interpret and report on germline variants, including support for NGS comprehensive cancer panels testing for both somatic and inherited cancers.

The product now includes comprehensive curation of the hereditary cancer literature and curated clinical case counts for common heritable cancers including breast and ovarian cancer, Lynch syndrome, Peutz-Jegher syndrome, ataxia telangiectasia, neurofibromatosis, hereditary diffuse gastric cancer, familial prostate cancer, polyposis and more.